Principal Investigator for the COAST study ( OPT-302 + Eylea) is Dr Charles Wykoff, MD PhD, Director of Research, Retina Consultants of Texas and Deputy Chair for Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Texas.
Principal Investigator for the ShORe study (OPT-302 + Lucentis) is Professor Tomothy Jackson, PhD, FRCOphth, consultant ophthalmic surgeon at King's College, London.
Dr Jason Slakter, founder and Director of the Digital Angiography Reading Center (DARC) in New York, and Clinical Professor of Ophthalmology at NYU School of Medicine, will also provide expertise as a leading authority on ocular imaging.
Ann: Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting, page-12
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.010(2.27%) |
Mkt cap ! $553.9M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 45.5¢ | 43.5¢ | $417.7K | 934.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9400 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 26000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |